My watch list
my.bionity.com  
Login  

Canopy Biosciences Acquires Zellkraftwerk GmbH

06-May-2019

Canopy Biosciences, LLC, a leading provider of gene editing and gene expression products and services, announced today that it has acquired Zellkraftwerk GmbH, a leader in multiplex cytometry and a spinoff of Hannover Medical School founded by Dr Christian Hennig, Dr Jan Detmers and Ascenion. Leveraging its innovative ChipCytometry platform, Zellkraftwerk offers complete workflow solutions - including both products and research services - for high-content cytometry on cells and tissues. The combination of Canopy and Zellkraftwerk creates a unique “multi-omics” company that boasts a powerful union of genomics expertise with cutting-edge cell and tissue analysis solutions to best support customers in drug development research and biomarker discovery. Concurrent with the acquisition, Canopy closed a strategic growth investment from Ampersand Capital Partners.

Edward Weinstein, Ph.D., co-founder and CEO of Canopy Biosciences, said “I am excited to complete the transformational acquisition of Zellkraftwerk and begin our partnership with Ampersand. Ampersand’s expertise and resources will benefit Canopy as we build a broader product and service offering for our customers, and the Zellkraftwerk acquisition provides a meaningful contribution to this strategy.” Weinstein continued, “Zellkraftwerk founders Jan Detmers and Christian Hennig have built a truly differentiated offering within the cell and tissue analysis market, and we’re excited to add their unique expertise and technology platform to Canopy Biosciences.”

Cofounder of Zellkraftwerk, Jan Detmers added, “As the scientific community continues to appreciate the roles and relationships between genotypes, phenotypes, and the environment, the need for “multi-omic” approaches to biomarker discovery and functional biology research has never been clearer. We are excited to partner with Canopy Biosciences and Ampersand to enhance our capabilities, scale, and geographic reach in the US, Europe, and Asia as we strive to best serve the evolving needs of our customers.”

Frank Witney, Ph.D., Operating Partner at Ampersand and incoming Chairman of Canopy, said, “Ampersand invests in high quality teams who manage rapidly growing businesses with established leadership positions in their specific markets, and Canopy is a great example. We are thrilled to have the opportunity to partner with Ed and the rest of the Canopy management team as they expand their gene editing and genomics analysis portfolio in combination with Zellkraftwerk’s unprecedented multiplex cytometry technology.” Canopy was formed in 2016 by BioGenerator, the funding arm of BioSTL in St. Louis, MO. Charlie Bolten, Senior Vice President of BioGenerator added “Canopy’s product portfolio is a result of a strategic approach to identify novel technologies and quickly commercialize products and services that will make an immediate impact on today’s biomedical research. BioGenerator is proud to have played a role in the founding of this company and is excited at Canopy’s continued growth prospects in partnership with Ampersand.”

Facts, background information, dossiers
More about Zellkraftwerk
  • Companies

    Zellkraftwerk GmbH

    We offer complete workflows for high content cytometry on cells and tissues – not just stand-alone solutions like reagents, robots or software. We apply principles of the 4th industrial revolution to provide products and services for the automated analysis of fluorescent biomarkers on livin ... more

More about Ascenion
  • News

    BioVaria Start-up Awards go to ISD Immunotech and Mindpax.me

    The 12th BioVaria welcomed over 250 life-science innovators to Munich, including biopharma executives, investors, academic inventors, entrepreneurs and technology transfer experts. There were 67 peer-selected licensing opportunities on offer, originating from as many research institutes, un ... more

    BioVaria Startup Awards go to OPSYON and LIfT Biosciences

    Over 250 innovative minds gathered in Munich for the 11th BioVaria to discuss emerging life-science trends and initiate partnerships between academia and industry. 63 peer-selected, patent-protected technologies originating from as many research institutes, universities and university hospi ... more

    OMEICOS Secures Extension of Series B Financing Round

    OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases, today announced that it has secured an extension of its recently closed Series B financing round. The financing b ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE